Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (91-100 of 332) with videos related to

Pageof 34
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 6, 2009
Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancerFloris Pos, Axel Bex, Hermina Maria Dees-Ribbers, et al.
Urology|February 15, 2005
Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancerAxel Bex, Jakko A Nieuwenhuijzen, Martijn Kerst, et al.
BJU International|July 9, 2020
Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomyAziz Gulamhusein, Pedro Silva, David Cullen, et al.
BJU International|April 2, 2025
Caval thrombectomy a urological leap into the unknown - a call for actionMartin John Connor, David Nicol, Walter Cazzanigna, et al.
European Urology|December 18, 2013
Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerationsAxel Bex, Laure Fournier, Nathalie Lassau, et al.
BMC Cancer|February 24, 2024
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-TrialLaura Iisager, Johanne Ahrenfeldt, Frede Donskov, et al.
The Cochrane Database of Systematic Reviews|October 15, 2020
Targeted therapy for metastatic renal cell carcinomaFabian Hofmann, Eu Chang Hwang, Thomas Bl Lam, et al.
Lancet (London, England)|July 21, 2024
Renal cell carcinomaMatthew Young, Francesca Jackson-Spence, Luis Beltran, et al.
Urologia Internationalis|July 1, 2008
Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysisAxel Bex, John B A G Haanen, Florry A Vyth-Dreese, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 4, 2026
Loss of ARID1A expression is associated with worse survival and reduced tumor infiltrating lymphocytes in advanced clear cell renal cell carcinomaMohamed Ashraf Mansour, Reshmi Patel, Faiz Mumtaz, et al.
Pageof 34

Showing results (91-100 of 332) with videos related to

Sort By:
Pageof 34
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 6, 2009
Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancerFloris Pos, Axel Bex, Hermina Maria Dees-Ribbers, et al.
Urology|February 15, 2005
Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancerAxel Bex, Jakko A Nieuwenhuijzen, Martijn Kerst, et al.
BJU International|July 9, 2020
Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomyAziz Gulamhusein, Pedro Silva, David Cullen, et al.
BJU International|April 2, 2025
Caval thrombectomy a urological leap into the unknown - a call for actionMartin John Connor, David Nicol, Walter Cazzanigna, et al.
European Urology|December 18, 2013
Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerationsAxel Bex, Laure Fournier, Nathalie Lassau, et al.
BMC Cancer|February 24, 2024
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-TrialLaura Iisager, Johanne Ahrenfeldt, Frede Donskov, et al.
The Cochrane Database of Systematic Reviews|October 15, 2020
Targeted therapy for metastatic renal cell carcinomaFabian Hofmann, Eu Chang Hwang, Thomas Bl Lam, et al.
Lancet (London, England)|July 21, 2024
Renal cell carcinomaMatthew Young, Francesca Jackson-Spence, Luis Beltran, et al.
Urologia Internationalis|July 1, 2008
Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysisAxel Bex, John B A G Haanen, Florry A Vyth-Dreese, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 4, 2026
Loss of ARID1A expression is associated with worse survival and reduced tumor infiltrating lymphocytes in advanced clear cell renal cell carcinomaMohamed Ashraf Mansour, Reshmi Patel, Faiz Mumtaz, et al.
Pageof 34